Erectile dysfunction: the earliest sign of generalized vascular disease?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Cheitlin, Melvin D.
EDITORIAL COMMENT
Erectile Dysfunction:
The Earliest Sign of
Generalized Vascular Disease?*
Melvin D. Cheitlin, MD, FACC
San Francisco, California
Until sildenafil, the first effective oral agent for erectile
dysfunction (ED), was introduced, only genitourinary phy-
sicians concerned themselves with this problem. Certainly
cardiologists rarely asked their patients with cardiovascular
disease about difficulty developing or maintaining a penile
erection. Physicians knew that ED could be caused by
atherosclerosis of the internal iliac arteries, the smaller
vessels supplying the penis, neural damage frequently related
to radical prostatectomy, certain medications, and a defi-
ciency of testosterone. Lacking these, ED was attributed to
psychologic problems.
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With the development of sildenafil, the first guanosine
monophosphate (GMP)-specific phosphodiesterase (PDE-5)
inhibitor, there has been a major increase in the interest in
the problem of ED, and with this increased interest, a
realization that the prevalence of ED in patients with
cardiovascular disease is higher than that of the general
population. There will soon be other PDE-5 inhibitors
approved by the Food and Drug Administration, such as
vardenafil and tadalafil, each with slightly different proper-
ties, so physicians will soon have several effective drugs with
which to treat these patients. In the Massachusetts Male
Aging Study, 34.8% of men ages 40 to 70 years have
moderate-to-complete ED, and 15% of men aged 70 have
complete ED. The risk increases markedly with age, with
men ages 50 to 59 having 3.6 times the risk of men age 18
to 29 (1). Studies have shown a high prevalence of ED in
patients with cardiovascular disease (1). There is a signifi-
cant correlation between the severity of ED and the number
of vessels involved in patients with coronary artery disease
(CAD) (2). The age-adjusted prevalence of complete ED is
1.5 times higher in men with hypertension than the prev-
alence in the entire population studied (1). Erectile dysfunc-
tion also is prevalent in smokers (3), diabetics (4), and
patients with hypercholesterolemia (5), all of the same risk
factors as for CAD. Conversely, patients with ED have an
increased prevalence of vascular disease, including CAD and
peripheral vascular disease (5).
The common denominator for these apparently disparate
problems is endothelial dysfunction, a major etiology of ED
(6). Penile erection occurs through neural stimulation of the
endothelial lining of penile vessels and the lacunae of the
corpus cavernosum, releasing nitric oxide. This activates
guanylate cyclase-converting guanosine triphosphate into
the second messenger cyclic GMP (cGMP), which through
cGMP-dependent protein kinase phosphorylates numerous
ion channels and pumps sequestering intracellular Ca2 in
the endoplasmic reticulum, decreasing cytosolic Ca2 and
resulting in smooth muscle relaxation, arteriolar vasodilata-
tion, and relaxation of the corpus cavernosum lacunae.
Intercourse stimulates the bulbocavernous reflex, and the
contracting ischiocavernous muscles compress the base of
the engorged corpus cavernosum. The lacunae fill with
arterial blood under arterial pressure, swelling the penis,
compressing the penile veins against the tough tunica
albuginea, and trapping blood in the corpus cavernosum
under arterial pressure (7). Detumescence occurs because
the cGMP is hydrolyzed to GMP by an enzyme, PDE-5,
one of a family of 11 PDE enzymes, allowing vasoconstric-
tion and lacunae to contract with release of blood from the
penis (8). Sildenafil, a PDE-5 inhibitor, prolongs the action
of cGMP and, therefore, smooth muscle relaxation.
Our present understanding of the genesis of atheroscle-
rosis also begins with damage to the intima of arteries,
accelerated by the risk factors such as smoking, hyperten-
sion, and so on, resulting in endothelial dysfunction. Ex-
cessive production of superoxide radicals and other reactive
oxygen species oxidizes lipoproteins, nucleic acids, and other
proteins. It also decreases nitric oxide bioavailability and
results in a procoagulant surface (9). Therefore, the earliest
events in the development of atherosclerosis are similar to
the earliest events in the development of ED.
Because of the high prevalence of vascular disease in
patients with ED, physicians must be aware of the relation-
ship and evaluate the patient for the presence of vascular
disease. Similarly, patients being examined for vascular
disease should be questioned about the presence of ED, first
because ED may be an important factor in degrading the
quality of life in some, if not all patients, and second because
we have an effective therapy that can markedly improve the
ED.
In this issue of the Journal, Kaiser et al. (10) have reported
a study of 30 patients with ED, with no clinical evidence of
arterial disease, who had most of the known risk factors
associated with coronary disease ruled out. Kaiser and
colleagues age-matched these patients with a control group
of normal subjects without clinical evidence of arterial
disease and without ED and searched for early signs of
atherosclerosis with carotid ultrasound, measuring thickness
of the intima-media, carotid and brachial artery compliance
and distensibility, aortic pulse wave velocity as a measure of
arterial stiffness, coronary calcification by rapid computed
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tomography, and brachial artery endothelium-dependent
and -independent vasodilatation.
They found no differences in intimal-medial thickness,
coronary calcification, or pulse wave velocity or aortic
distensibility, all presumably surrogates for atherosclerosis,
from the control subjects. They found abnormal
endothelial-dependent flow-mediated vasodilatation in the
brachial arteries in the patients with ED, indicating a
widespread abnormality of endothelial function in men with
ED as has been shown in patients with CAD (11) and
CAD risk factors (12). Their conclusion was that ED is the
earliest manifestation of vascular disease and that these
patients may be at increased risk of later developing clini-
cally apparent arterial disease, including CAD. Further-
more, they noted that endothelial dysfunction occurred in
the absence of the usual atherosclerosis risk factors in these
patients. The question arises as to whether all known risk
factors were ruled out: lipoprotein (a), elevated homocys-
teine, glucose intolerance, and insulin resistance were not
examined. It is possible that the patients had risk factors
predisposing them to atherosclerosis. Still, the earliest sign
before any demonstrable vascular disease was the develop-
ment of ED.
There are etiologies of ED other than endothelial dys-
function, such as damage to the penile autonomic innerva-
tion as seen in radical prostatectomy (13). However, in this
study ED was determined to be vascular in etiology by using
a Doppler technique to determine cavernosal artery velocity
as a measure of penile blood flow. Even if atherosclerosis
and some patients with ED have a common abnormality of
endothelial dysfunction, there are patients where ED may
be related to any of the stages in the cascade of chemical
processes that produce smooth muscle relaxation and vaso-
dilatation. For instance, the cGMP-dependent protein ki-
nase activation of the Ca2-sensitive potassium channels,
which hyperpolarize the arterial and cavernosal smooth
muscle cell membranes causing relaxation, appears to be
compromised with aging and may not be associated with a
higher incidence of development of arterial disease (14).
This abnormality is at the level of the smooth muscle cell.
Corporeal veno-occlusive dysfunction, a smooth muscle
problem that causes venous leakage from the penis, is
another etiology of ED that does not produce decreased
blood flow into the corpus cavernosum (15) and yet may not
be a harbinger of atherosclerosis.
An interesting finding in this study is that both
endothelial-dependent and endothelial-independent vaso-
dilatation were abnormal in patients with ED. The impli-
cation is that, in these ED patients without signs of early
atherosclerosis, the problem is not only endothelial dysfunc-
tion but also a problem with smooth muscle relaxation itself.
A possible explanation for this finding is that with long-
standing penile vascular disease, either atherosclerotic or
due to endothelial dysfunction, a loss of smooth muscle and
fibrosis occur in the corpus cavernosum, which will cause
the ED to persist despite reversal of the original vascular
abnormality (16,17). Still, evidence that there is a smooth
muscle abnormality beyond the endothelial dysfunction in
ED is an intriguing finding and certainly will have to be
confirmed by other studies.
The important message here is that many patients with
ED have a vascular mechanism similar to that seen in
atherosclerosis and that its presence should alert the clini-
cian to the possible presence or future development of
vascular disease. To paraphrase Richardson and Vinik: “a
flagging penis should raise the red flag of warning to
evaluate the patient for arterial disease elsewhere” (18).
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